AVITA Medical to Host Investor Webinar Briefing

Rhea-AI Summary

AVITA Medical (NASDAQ: RCEL) will host an investor webinar briefing on Feb 18, 2026 at 2:00 PM PST (Feb 19, 2026 at 9:00 AM AEDT).

Interim CEO Cary Vance and CFO David O’Toole will review fourth-quarter and full-year 2025 financial and business results, followed by a Q&A. A replay will be posted on the company investor site.

Market Reaction

+18.55% $4.41

15m delay 21 alerts

+18.55% Since News

$4.41 Last Price

$3.52 $4.41 Day Range

+$21M Valuation Impact

$134M Market Cap

0.8x Rel. Volume

Following this news, RCEL has gained 18.55%, reflecting a significant positive market reaction. Our momentum scanner has triggered 21 alerts so far, indicating elevated trading interest and price volatility. The stock is currently trading at $4.41. This price movement has added approximately $21M to the company's valuation.

Data tracked by StockTitan Argus (15 min delayed). Upgrade to Silver for real-time data.

VALENCIA, Calif., Feb. 13, 2026 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (ASX: AVH, NASDAQ: RCEL), a leading therapeutic acute wound care company delivering transformative solutions, invites shareholders and prospective investors to attend its investor webinar briefing and presentation by Cary Vance, Interim Chief Executive Officer, and David O’Toole, Chief Financial Officer, on February 18, 2026, at 2:00 p.m. Pacific Standard Time (February 19, 2026, at 9:00 a.m. Australian Eastern Daylight Time).

The webinar presentation will cover financial and business results from AVITA Medical’s recent fourth-quarter and full-year 2025 earnings webcast and will conclude with a Q&A session. Participants are invited to submit their questions via the registration page.

To register for the presentation, please follow this Zoom link:
https://us06web.zoom.us/webinar/register/WN_F_ldbJWLS1SQqUKIjfwFWQ

A replay will be available on the AVITA Medical website at: https://ir.avitamedical.com/

About AVITA Medical, Inc.

AVITA Medical^® is a leading therapeutic acute wound care company delivering transformative solutions. Our technologies are designed to optimize wound healing, effectively accelerating the time to patient recovery. At the forefront of our platform is the RECELL^®, approved by the FDA for the treatment of thermal burn and trauma wounds. RECELL harnesses the healing properties of a patient’s own skin to create Spray-On Skin™, offering an innovative solution for improved clinical outcomes at the point-of-care. In the U.S., AVITA Medical also holds the exclusive rights to manufacture, market, sell, and distribute PermeaDerm^®, a biosynthetic wound matrix, and the exclusive rights to market, sell, and distribute Cohealyx™, an AVITA Medical-branded collagen-based dermal matrix.

In international markets, RECELL is approved to promote skin healing in a wide range of applications including thermal burn and trauma wounds. RECELL and RECELL GO^® have received the CE mark in Europe; and RECELL is TGA-registered in Australia, and has PMDA approval in Japan.

To learn more, visit www.avitamedical.com.

Investor & Media Contact:
Ben Atkins
Phone +1-805 341 1571
investor@avitamedical.com
media@avitamedical.com

Authorized for release by the Chief Financial Officer of AVITA Medical, Inc.

©2026 AVITA Medical. AVITA Medical^®, Cohealyx^®, RECELL^®, RECELL GO^®, and Spray-On Skin^TM are trademarks of AVITA Medical. PermeaDerm^® is a registered trademark owned by Stedical Scientific, Inc. All other trademarks are the properties of their respective owners.

FAQ

When is the AVITA Medical (RCEL) investor webinar briefing scheduled?

The webinar is scheduled for Feb 18, 2026 at 2:00 PM PST (Feb 19, 2026 at 9:00 AM AEDT). According to AVITA Medical, the briefing will include a presentation and a live Q&A with management.

Who will present at the AVITA Medical (RCEL) investor webinar on Feb 18, 2026?

Presenters are Interim CEO Cary Vance and CFO David O’Toole. According to AVITA Medical, they will review fourth-quarter and full-year 2025 financial and business results and take investor questions during Q&A.

How can investors register for the AVITA Medical (RCEL) February 2026 webinar?

Investors can register via the provided Zoom registration link. According to AVITA Medical, registrants may submit questions in advance through the registration page before the Feb 18, 2026 briefing.

Will a replay of the AVITA Medical (RCEL) Feb 18, 2026 webinar be available?

Yes, a replay will be available on the company investor website. According to AVITA Medical, the replay will be posted after the presentation for shareholders and prospective investors to review.

What topics will AVITA Medical (RCEL) cover in the Feb 18, 2026 investor webinar?

The webinar will cover fourth-quarter and full-year 2025 financial and business results. According to AVITA Medical, the session includes management commentary and a live Q&A to address investor questions.